SciELO - Scientific Electronic Library Online

 
vol.78 issue4COVID-19 and Cutaneous Disorders: What’s Being Reported? A Meta-Analysis from Observational Studies and Case ReportsPhototherapy in Pediatric Population: Particularities and Indications author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • Have no similar articlesSimilars in SciELO

Share


Revista da Sociedade Portuguesa de Dermatologia e Venereologia

Print version ISSN 2182-2395On-line version ISSN 2182-2409

Abstract

SILVA, Leandro  and  BORGES-COSTA, João. Cutaneous Squamous Cell Carcinoma in Solid Organ Transplant Patients. Rev Soc Port Dermatol Venereol [online]. 2020, vol.78, n.4, pp.34-40.  Epub Sep 10, 2021. ISSN 2182-2395.  https://doi.org/10.29021/spdv.78.4.1270.

Solid organ transplant recipients (SOTR) are more likely to develop cutaneous squamous cell carcinoma (CSCC), compared to the general population. This increased incidence is due to several factors including chronic ultraviolet radiation exposure, human papillomavirus (HPV) infection, immunosuppressive medication, among others. Primary prevention is crucial, because not only are cutaneous squamous cell carcinomas more frequent in SOTR, but they are also more aggressive and have therefore a worse prognosis. Newer immunosuppressive drugs are associated with a smaller risk of developing CSCC, but they can have more adverse events, prompting patients to abandon therapy. Concerning treatment options for CSCC, they range from surgery, radiotherapy, and systemic therapy, although there are few studies in SOTR concerning the use of immunotherapy and epidermal growth factor receptor (EGFR) inhibitors.

Keywords : Carcinoma, Squamous Cell; Immunosuppression/adverse effects; Skin Neoplasms; Transplant Recipients..

        · abstract in Portuguese     · text in English     · English ( pdf )